UO Ematologia Ospedale di Circolo e Fondazione Macchi
Welcome,         Profile    Billing    Logout  
 9 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Passamonti, Francesco
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting
2
21
Europe, US, RoW
GB2064
Galecto Biotech AB, OPIS s.r.l
Myelofibrosis
12/23
06/26
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
NCT04878822: Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies

Active, not recruiting
N/A
300
Europe
Ospedale di Circolo - Fondazione Macchi
Immunogenicity, Hematological Malignancies, Covid-19, Vaccine Response Impaired
07/21
04/23
TFR-PRO, NCT04621851: Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation

Recruiting
N/A
3000
Europe, Canada
University of Milano Bicocca
Chronic Myeloid Leukemia
09/21
09/23
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
FISiM-NGS-MDS, NCT04212390: Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care

Recruiting
N/A
1000
Europe
Fondazione Italiana Sindromi Mielodisplastiche-ETS
MDS (Myelodysplastic Syndrome)
03/24
03/25
REALFed, NCT05883904: Real World Evidence of Fedratinib Effectiveness in MF

Recruiting
N/A
93
Europe
Fedratinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
01/26
01/26

Download Options